Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy

The patient was a 65-year-old man with alcoholic liver cirrhosis who had been admitted to hospital 5 times for repeated and recurrent overt hepatic encephalopathy (HE) despite numerous therapies, including disaccharide, branched-chain amino acid (BCAA) formula, L-carnitine and zinc. After the additi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yudai, Suzuki, Kazuyuki, Yusa, Kenji, Eizuka, Makoto, Miura, Manami, Watanabe, Yuki, Takahashi, Hiroshi, Takikawa, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079929/
https://www.ncbi.nlm.nih.gov/pubmed/33790139
http://dx.doi.org/10.2169/internalmedicine.5793-20
_version_ 1783685321474441216
author Fujiwara, Yudai
Suzuki, Kazuyuki
Yusa, Kenji
Eizuka, Makoto
Miura, Manami
Watanabe, Yuki
Takahashi, Hiroshi
Takikawa, Yasuhiro
author_facet Fujiwara, Yudai
Suzuki, Kazuyuki
Yusa, Kenji
Eizuka, Makoto
Miura, Manami
Watanabe, Yuki
Takahashi, Hiroshi
Takikawa, Yasuhiro
author_sort Fujiwara, Yudai
collection PubMed
description The patient was a 65-year-old man with alcoholic liver cirrhosis who had been admitted to hospital 5 times for repeated and recurrent overt hepatic encephalopathy (HE) despite numerous therapies, including disaccharide, branched-chain amino acid (BCAA) formula, L-carnitine and zinc. After the additional administration of rifaximin (1,200 mg/day orally), his consciousness level was well controlled for 3 years without any adverse effects. The long-term administration of rifaximin may be useful and safe for managing recurrent overt HE, although the maintenance dosage and duration of rifaximin and safety should be evaluated in patients with ameliorated HE.
format Online
Article
Text
id pubmed-8079929
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-80799292021-05-11 Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy Fujiwara, Yudai Suzuki, Kazuyuki Yusa, Kenji Eizuka, Makoto Miura, Manami Watanabe, Yuki Takahashi, Hiroshi Takikawa, Yasuhiro Intern Med Case Report The patient was a 65-year-old man with alcoholic liver cirrhosis who had been admitted to hospital 5 times for repeated and recurrent overt hepatic encephalopathy (HE) despite numerous therapies, including disaccharide, branched-chain amino acid (BCAA) formula, L-carnitine and zinc. After the additional administration of rifaximin (1,200 mg/day orally), his consciousness level was well controlled for 3 years without any adverse effects. The long-term administration of rifaximin may be useful and safe for managing recurrent overt HE, although the maintenance dosage and duration of rifaximin and safety should be evaluated in patients with ameliorated HE. The Japanese Society of Internal Medicine 2021-04-01 2021-04-01 /pmc/articles/PMC8079929/ /pubmed/33790139 http://dx.doi.org/10.2169/internalmedicine.5793-20 Text en Copyright © 2021 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Fujiwara, Yudai
Suzuki, Kazuyuki
Yusa, Kenji
Eizuka, Makoto
Miura, Manami
Watanabe, Yuki
Takahashi, Hiroshi
Takikawa, Yasuhiro
Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
title Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
title_full Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
title_fullStr Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
title_full_unstemmed Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
title_short Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
title_sort evaluation of the long-term administration of rifaximin for more than three years in the treatment of repeated and recurrent overt hepatic encephalopathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079929/
https://www.ncbi.nlm.nih.gov/pubmed/33790139
http://dx.doi.org/10.2169/internalmedicine.5793-20
work_keys_str_mv AT fujiwarayudai evaluationofthelongtermadministrationofrifaximinformorethanthreeyearsinthetreatmentofrepeatedandrecurrentoverthepaticencephalopathy
AT suzukikazuyuki evaluationofthelongtermadministrationofrifaximinformorethanthreeyearsinthetreatmentofrepeatedandrecurrentoverthepaticencephalopathy
AT yusakenji evaluationofthelongtermadministrationofrifaximinformorethanthreeyearsinthetreatmentofrepeatedandrecurrentoverthepaticencephalopathy
AT eizukamakoto evaluationofthelongtermadministrationofrifaximinformorethanthreeyearsinthetreatmentofrepeatedandrecurrentoverthepaticencephalopathy
AT miuramanami evaluationofthelongtermadministrationofrifaximinformorethanthreeyearsinthetreatmentofrepeatedandrecurrentoverthepaticencephalopathy
AT watanabeyuki evaluationofthelongtermadministrationofrifaximinformorethanthreeyearsinthetreatmentofrepeatedandrecurrentoverthepaticencephalopathy
AT takahashihiroshi evaluationofthelongtermadministrationofrifaximinformorethanthreeyearsinthetreatmentofrepeatedandrecurrentoverthepaticencephalopathy
AT takikawayasuhiro evaluationofthelongtermadministrationofrifaximinformorethanthreeyearsinthetreatmentofrepeatedandrecurrentoverthepaticencephalopathy

Ejemplares similares